Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study.
Derek WeyckerRobin DoroffAhuva HanauCharles BowersRajesh BelaniDavid ChandlerAlexander LonshteynMark BensinkGary H LymanPublished in: BMC cancer (2019)
Notwithstanding clinical practice guidelines, a large minority of patients did not receive G-CSF prophylaxis, and FN incidence was substantially higher among this subset of the population. Appropriate use of pegfilgrastim prophylaxis may reduce patient exposure to this potentially fatal but largely preventable complication of myelosuppressive chemotherapy.
Keyphrases
- end stage renal disease
- clinical practice
- ejection fraction
- randomized controlled trial
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- chemotherapy induced
- risk factors
- case report
- locally advanced
- emergency department
- squamous cell carcinoma
- cerebrospinal fluid
- patient reported
- rectal cancer